Integra LifeSciences appoints Lea Daniels Knight as EVP and CFO effective June 28

INTEGRA LIFESCIENCES HOLDINGS CORP

Knight brings over 30 years of experience, most recently as EVP Business Finance at Booz Allen Hamilton, and 18 years at Johnson & Johnson.
Compensation includes $600K base salary, 90% target bonus, $1M RSU grant, $350K cash sign-on, and $1.65M 2024 LTI target.
Jeff Mosebrook ceases as principal financial officer but remains SVP Finance and principal accounting officer.
Appointment effective June 28, 2023; Knight succeeds interim CFO role held since February 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lea Daniels Knight

Executive Vice President and Chief Financial Officer

IART · INTEGRA LIFESCIENCES HOLDINGS CORP

Effective: 2023-06-28
Filed: June 21, 2023, 7:59 PM ET

On June 21, 2023, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Lea Daniels Knight to serve as its Executive Vice President and Chief Financial Officer effective June 28, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Lea Daniels Knight was appointed as Executive Vice President and Chief Financial Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On June 21, 2023, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Lea Daniels Knight to serve as its Executive Vice President and Chief Financial Officer effective June 28, 2023.

View on SEC.gov

INTEGRA LIFESCIENCES HOLDINGS CORP filing history →

Source: SEC EDGAR

accession 0000917520-23-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.